UPCC 08520: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This is an umbrella research study is designed to learn more about the safety and effectiveness of AMG 510 in combination with different investigational agents. Eligible subjects include adults with KRAS p.G12C Mutation.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 843910
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
